Modified Response Evaluation Criteria in Solid Tumors (mRECIST)

ورودی‌های بالینی بیمار

حداقل ۰.۱ — حداکثر ۵۰ • واحد: cm

حداقل ۰ — حداکثر ۵۰ • واحد: cm

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
mrecist response
—response_category
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Complete Response—
  • Partial Response—
  • Stable Disease—
  • Progressive Disease—
Direct Clinical Answer

The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) calculator is designed for bedside assessing treatment response in hepatocellular carcinoma (HCC) patients based on viable tumor enhancement, specifically designed for patients receiving targeted therapies and locoregional treatments in clinical practice. The resulting score directly guides.

Clinical Guidelines & Evidence

Assesses treatment response in hepatocellular carcinoma (HCC) patients based on viable tumor enhancement, specifically designed for patients receiving targeted therapies and locoregional treatments.

Clinical Indication

The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) is indicated for bedside clinical practice to support Assesses treatment response in hepatocellular carcinoma (HCC) patients based on viable tumor enhancement, specifically designed for patients receiving targeted therapies and locoregional treatments.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: European Association for the Study of the Liver (EASL) guidelines recommend evaluation 1 month after treatment.

Formula & Variables:

mRECIST Response = f(baseline_sum_diameters, current_sum_diameters, enhancement_status). Complete Response: disappearance of arterial enhancement. Partial Response: ≥30% decrease in viable tumor. Progressive Disease: ≥20% increase in viable tumor or new lesions. Stable Disease: neither PR nor PD criteria.

Input Parameters

NameTypeRequiredDescription
baseline_sum_diametersfloatYesSum of baseline diameters of viable (enhancing) target lesions in centimeters(cm)
current_sum_diametersfloatYesSum of current diameters of viable (enhancing) target lesions in centimeters(cm)
intratumoral_enhancementstringYesPresence of intratumoral arterial enhancement in target lesions

Score Interpretation & Guidance

RangeStageDescription
—Complete ResponseDisappearance of arterial enhancement
—Partial Response≥30% decrease in viable tumor
—Stable DiseaseNeither PR nor PD criteria met
—Progressive Disease≥20% increase in viable tumor

Evidence-Based References (EBM)

  • Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60. doi: 10.1055/s-0030-1247132.DOI: 10.1055/s-0030-1247132
  • Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115(3):616-23. doi: 10.1002/cncr.24050.DOI: 10.1002/cncr.24050
  • Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012;118(1):147-56. doi: 10.1002/cncr.26255.DOI: 10.1002/cncr.26255

Related calculators